Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis.
about
Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.Effects of a7nAChR agonist on the tissue estrogen receptor expression of castrated rats.Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery
P2860
Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis.
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Type 2 17-β hydroxysteroid deh ...... the treatment of osteoporosis.
@ast
Type 2 17-β hydroxysteroid deh ...... the treatment of osteoporosis.
@en
Type 2 17-β hydroxysteroid deh ...... the treatment of osteoporosis.
@nl
type
label
Type 2 17-β hydroxysteroid deh ...... the treatment of osteoporosis.
@ast
Type 2 17-β hydroxysteroid deh ...... the treatment of osteoporosis.
@en
Type 2 17-β hydroxysteroid deh ...... the treatment of osteoporosis.
@nl
prefLabel
Type 2 17-β hydroxysteroid deh ...... the treatment of osteoporosis.
@ast
Type 2 17-β hydroxysteroid deh ...... the treatment of osteoporosis.
@en
Type 2 17-β hydroxysteroid deh ...... the treatment of osteoporosis.
@nl
P2093
P2860
P356
P1476
Type 2 17-β hydroxysteroid deh ...... the treatment of osteoporosis.
@en
P2093
François Dufrasne
Ibaa Chikh Alard
Jalal Soubhye
Pierre van Antwerpen
P2860
P304
P356
10.4155/FMC.15.74
P577
2015-08-01T00:00:00Z